Balciunaite Egle, Kazlauskas Andrius
Schepens Eye Research Institute, Harvard Medical School, Boston, Massachusetts 02114, USA.
Exp Cell Res. 2002 Dec 10;281(2):167-74. doi: 10.1006/excr.2002.5659.
In response to natural agonists, such as platelet-derived growth factor (PDGF), diacylglycerol-responsive protein kinase Cs (PKCs) are activated at two distinct times, early and mid G1, and only the late activity is required for the transition into S phase. Surprisingly, the potent PKC activator phorbol 12-myristate 13-acetate (PMA) inhibits DNA synthesis when it is added in mid G1. Here we investigated why different PKC agonists had opposing effects on cell proliferation. We found that the magnitude and timing of PKC activation determined their ability to suppress DNA synthesis. Furthermore, potent activation of PKCs resulted in robust Erk activation and elevation of p21(CIP1). Finally, PMA was unable to block PDGF-dependent cell cycle progression in cells that lack p21(CIP1). These findings indicate that only potent activators of PKC were capable of blocking cell cycle progression, and the mechanism appears to involve an elevation of p21(CIP1).
作为对天然激动剂(如血小板衍生生长因子,PDGF)的反应,二酰基甘油反应性蛋白激酶C(PKC)在两个不同时间点被激活,即G1期早期和中期,并且只有后期的活性对于进入S期是必需的。令人惊讶的是,强效PKC激活剂佛波醇12 - 肉豆蔻酸酯13 - 乙酸酯(PMA)在G1期中期添加时会抑制DNA合成。在此,我们研究了为何不同的PKC激动剂对细胞增殖有相反的作用。我们发现PKC激活的程度和时间决定了它们抑制DNA合成的能力。此外,PKC的强效激活导致Erk的强烈激活以及p21(CIP1)水平升高。最后,PMA在缺乏p21(CIP1)的细胞中无法阻断PDGF依赖性细胞周期进程。这些发现表明只有PKC的强效激活剂能够阻断细胞周期进程,并且其机制似乎涉及p21(CIP1)水平的升高。